Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85 in infants and toddlers with moderate atopic dermatitis
NL-OMON54004Phase 2Completed
- Sponsor
- OM Pharma
- Start
- Feb 2023
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OM-85 in atopic dermatitis (AD), sponsored by OM Pharma. Started Feb 2023; status: completed.
02
Drugs
OM-85
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON54004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54004.